Over $14 billion spent on migranes annually in the US and Nupathe has proprietary delivery system that will target a good chunk of this huge pie.

PDUFA date set at January 17, which means we should see some steady appreciation in stock price til then regardless of what the eventual FDA decision is. A yes vote will undoubtedly have a huge impact on the small market cap and tight float.

A great biotech to keep your eye on as the PDUFA date is now less than 2 months away.

www.nupathe.com